CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

In a statement posted to the newsroom of Hims & Hers (HIMS), Craig Primack ... that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform.

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli ...

“We find it incredibly unlikely a consumer would go to HIMS to buy any branded GLP-1 for $1,899/month.” Instead, analysts are waiting to see on how well the company’s generic liraglutide perform ...